PLUVICTO
lutetium lu 177 vipivotide tetraxetan
Quick Facts
Indications and Usage
PLUVICTO is a radioactive medicine used to treat PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that has spread to other parts of the body.
PLUVICTO is a radioactive medicine used to treat PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that has spread to other parts of the body.
Dosage and Administration
The recommended dose is 200 mCi given through an IV every 6 weeks for up to 6 doses.
The recommended dose is 200 mCi given through an IV every 6 weeks for up to 6 doses.
Contraindications
Pregnancy, breastfeeding, and patients with severe kidney problems.
Pregnancy, breastfeeding, and patients with severe kidney problems.
Warnings and Precautions
This medicine can lower blood counts, harm kidneys, and expose you to radiation. Your doctor will check your blood and kidney function.
This medicine can lower blood counts, harm kidneys, and expose you to radiation. Your doctor will check your blood and kidney function.
Adverse Reactions
Feeling very tired, dry mouth, upset stomach, low red blood cells, low white blood cells, low platelets, low infection-fighting cells.
Feeling very tired, dry mouth, upset stomach, low red blood cells, low white blood cells, low platelets, low infection-fighting cells.
Drug Interactions
May interact with other medicines or treatments that affect your bone marrow.
May interact with other medicines or treatments that affect your bone marrow.
Mechanism of Action
PLUVICTO sticks to a protein called PSMA on prostate cancer cells and delivers targeted radiation using lutetium-177.
PLUVICTO sticks to a protein called PSMA on prostate cancer cells and delivers targeted radiation using lutetium-177.